Auf dieser Seite
TSHA Taysha Gene Therapies, Inc. - Common Stock
NASDAQ · Biotechnology · Auf SEC EDGAR ansehen ↗ Schließen Okt 2, 2026 10-K/10-Q Aug 11, 2026
$4,63
· % der 52-Wochen-Spanne
· über Tiefststand
· zu hoch
$3,6952-Wochen-Tief
$7,3052-Wochen-Hoch
Marktkapitalisierung (MRQ)
$1.51B
P/E (TTM)
-11.0
EPS (TTM)
$-0.42
Umsatz (TTM)
$5M
Ihre Abzeichen
52W-Spanne
$4–$7
Analystenbewertung
BUY
Kursziel
$13
P/E
-11.0
ROE
-47.1%
Nettogewinnmarge
-2728.0%
Ihre Abzeichenleiste ist leer – heften Sie eine Kennzahl auf dieser Seite an.
TSHA Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$4.63
Marktkapitalisierung (MRQ)
$1.51B
P/E (TTM)
-11.0
EPS (TTM)
$-0.42
Umsatz (TTM)
$5M
ROE (TTM)
-47.1%
Verschuldungsgrad (MRQ)
0.1
52W-Spanne
$4–$7
TSHA Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Spanne
Balken
Die Balkengranularität passt sich der ausgewählten Periode an – bewegen Sie den Mauszeiger über das Diagramm, um Eröffnungs-/Höchst-/Tiefst-/Schlusskurse für einen Balken anzuzeigen.
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz$10M2022-12-31 → 2025-12-31
EPS$-0.342021-12-31 → 2025-12-31
Freier Cashflow$-94M2020-12-31 → 2025-12-31
Nettogewinnmarge-2728.0%2023-12-31 → 2025-12-31
Bewertung & Kennzahlen
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
| Kennzahl | 5-Jahres-Trend | TSHA | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| P/E (TTM) | -11.05-Jahres-Durchschnitt ≈-5.2 | ≈-5.2 | · | · | |
| P/S (TTM) | 274.65-Jahres-Durchschnitt ≈74.8 | ≈74.8 | 37.8 | Überbewertet | |
| K/B (MRQ) | 3.95-Jahres-Durchschnitt ≈5.1 | ≈5.1 | 3.3 | Überbewertet | |
| EV / EBITDA | -9.65-Jahres-Durchschnitt ≈-4.9 | ≈-4.9 | · | · | |
| Kurs / FCF (TTM) | -11.45-Jahres-Durchschnitt ≈-7.2 | ≈-7.2 | · | · | |
| Kurs / Cashflow (TTM) | -11.45-Jahres-Durchschnitt ≈-7.4 | ≈-7.4 | · | · | |
| EV / Revenue (EV / Umsatz) | 108.55-Jahres-Durchschnitt ≈59.6 | ≈59.6 | · | · | |
| EV / FCF | -11.35-Jahres-Durchschnitt ≈-5.6 | ≈-5.6 | · | · | |
| Price / Tangible Book (Kurs / Materieller Buchwert) | 5.45-Jahres-Durchschnitt ≈34.2 | ≈34.2 | · | · |
Der Median der Vergleichsgruppe wird pro Kennzahl standardisiert berechnet und stimmt möglicherweise nicht immer mit der für diese Aktie angezeigten TTM/MRQ-Basis überein.
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
| Kennzahl | 5-Jahres-Trend | TSHA | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Betriebsgewinnmarge (TTM) | -2792.3%5-Jahres-Durchschnitt ≈-899.0% | ≈-899.0% | -890.5% | Schwach | |
| EBITDA Margin (EBITDA-Marge) | -1130.7%5-Jahres-Durchschnitt ≈-899.0% | ≈-899.0% | -890.5% | Schwach | |
| Nettogewinnmarge (TTM) | -2728.0%5-Jahres-Durchschnitt ≈-969.7% | ≈-969.7% | -874.4% | Schwach | |
| ROA (TTM) | -37.2%5-Jahres-Durchschnitt ≈-61.3% | ≈-61.3% | -41.9% | Im Einklang | |
| ROE (TTM) | -47.1%5-Jahres-Durchschnitt ≈-291.9% | ≈-291.9% | -55.3% | Spitzenklasse |
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
| Kennzahl | 5-Jahres-Trend | TSHA | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Fremdkapital / Eigenkapital (MRQ) | 0.15-Jahres-Durchschnitt ≈0.4 | ≈0.4 | 0.1 | Im Einklang | |
| Liquiditätsgrad (MRQ) | 17.85-Jahres-Durchschnitt ≈6.2 | ≈6.2 | 6.5 | Starke Liquidität | |
| Quick Ratio | 12.05-Jahres-Durchschnitt ≈6.0 | ≈6.0 | 5.5 | Starke Liquidität | |
| Langfristige Schulden / Eigenkapital (MRQ) | 0.15-Jahres-Durchschnitt ≈0.4 | ≈0.4 | · | · |
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
| Kennzahl | 5-Jahres-Trend | TSHA | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Revenue YoY (Umsatz YoY) | 17.3%5-Jahres-Durchschnitt ≈162.9% | ≈162.9% | · | · | |
| Revenue CAGR 3Y (Umsatz CAGR 3J) | 57.5% | · | · | · |
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
| Kennzahl | 5-Jahres-Trend | TSHA | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Asset Turnover (Umsatz / Vermögenswerte) | 0.05-Jahres-Durchschnitt ≈0.1 | ≈0.1 | 0.1 | Schwach | |
| Revenue / Employee (Umsatz / Mitarbeiter) | ≈$98.7K | · | · | · |
Wert · ≈ 5-Jahres-Durchschnitt · Branchenmedian · Urteil relativ zum Median
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
0.53%
Nächster Bericht
Nov 02, 2026
| Zeitraum | Bericht | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|---|
| 30. Juni 2026 | Aug 17, 2026 | $-0.14 | $-0.12 | -17.7% |
| 31. März 2026 | Mai 20, 2026 | $-0.12 | $-0.10 | -20.5% |
| 31. Dezember 2025 | $-0.08 | $-0.10 | 18.5% | |
| 30. September 2025 | $-0.09 | $-0.09 | 0.00% | |
| 30. Juni 2025 | $-0.09 | $-0.08 | -9.1% | |
| 31. März 2025 | $-0.08 | $-0.09 | 15.3% | |
| 31. Dezember 2024 | $-0.07 | $-0.08 | 17.4% |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | $10M | $8M | $15M | $3M | |
| R&D Expense | $86M | $66M | $57M | $91M | |
| SG&A Expense | $34M | $29M | $30M | $37M | |
| Operating Expenses | $120M | $100M | $88M | $165M | |
| Operating Income | $-110M | $-91M | $-72M | $-162M | |
| Interest Expense | · | · | $5M | $4M | |
| Interest Income | $9M | $7M | $4M | · | |
| Other Non-op | $-291.0K | $-110.0K | $-47.0K | $-18.0K | |
| Income Tax | $0 | $0 | $0 | $0 | |
| Net Income | $-109M | $-89M | $-112M | $-166M | |
| EPS (Basic) | $-0.34 | $-0.36 | $-0.96 | $-3.78 | |
| EPS (Diluted) | $-0.34 | $-0.36 | $-0.96 | $-3.78 | |
| Shares (Basic) | 319,711,972 | 250,134,421 | 116,121,482 | 43,952,015 | |
| Shares (Diluted) | 319,711,972 | 250,134,421 | 116,121,482 | 43,952,015 | |
| EBITDA | $-110M | $-91M | $-72M | · |
Bilanz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Cash & Equivalents | $320M | $139M | $144M | $88M | |
| Prepaid Expense | $4M | $3M | $3M | $9M | |
| Other Current Assets | $802.0K | $308.0K | $292.0K | $466.0K | |
| Current Assets | $325M | $142M | $150M | $96M | |
| PP&E (Net) | $7M | $7M | $11M | $15M | |
| PP&E (Gross) | $11M | $11M | $14M | $17M | |
| Accum. Depreciation | $5M | $4M | $3M | $2M | |
| Other Non-current Assets | $183.0K | $217.0K | $304.0K | $1M | |
| Total Assets | $343M | $160M | $173M | $126M | |
| Accounts Payable | $6M | $4M | $6M | $11M | |
| Current Liabilities | $27M | $26M | $37M | $63M | |
| Capital Leases | $18M | $17M | $19M | $20M | |
| Other Non-current Liabilities | $2M | $1M | $2M | $4M | |
| Total Liabilities | $96M | $89M | $98M | $125M | |
| Long-term Debt | · | · | · | $38M | |
| Total Debt | $50M | $44M | $41M | · | |
| Common Stock | $3.0K | $2.0K | $2.0K | $1.0K | |
| Paid-in Capital | $958M | $678M | $588M | $402M | |
| Retained Earnings | $-711M | $-602M | $-513M | $-401M | |
| AOCI | $-192.0K | $-4M | · | · | |
| Stockholders' Equity | $247M | $72M | $75M | $949.0K | |
| Liabilities + Equity | $343M | $160M | $173M | $126M | |
| Shares Outstanding | 285,051,648 | 204,943,306 | 186,960,193 | 63,207,507 |
Cashflow
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Stock-based Comp | $13M | $13M | $8M | $18M | |
| Operating Cash Flow | $-93M | $-81M | $-73M | $-88M | |
| CapEx | $738.0K | $374.0K | $4M | $21M | |
| Investing Cash Flow | $-604.0K | $-363.0K | $-7M | $-25M | |
| Stock Issued | · | · | $500.0K | · | |
| Financing Cash Flow | $275M | $77M | $136M | $52M | |
| Net Change in Cash | $181M | $-5M | $56M | $-61M | |
| Free Cash Flow | $-94M | $-82M | $-77M | · |
Rentabilität
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Operating Margin | -1130.7% | -1097.5% | -468.8% | · | |
| Net Margin | -1115.3% | -1071.6% | -722.1% | · | |
| EBITDA Margin | -1130.7% | -1097.5% | -468.8% | · | |
| ROA | -43.3% | -53.6% | -74.6% | · | |
| ROE | -44.0% | -111.4% | -864.1% | · |
Liquidität & Solvenz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Current Ratio | 12.2 | 5.4 | 4.1 | · | |
| Quick Ratio | 12.0 | 5.3 | 3.9 | · | |
| Debt / Equity | 0.2 | 0.6 | 0.5 | · | |
| LT Debt / Equity | 0.2 | 0.6 | 0.5 | · | |
| Interest Coverage | · | · | -14.5 | · |
Effizienz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.1 | 0.1 | · |
Pro Aktie
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Book Value / Share | $0.87 | $0.35 | $0.40 | · | |
| Revenue / Share | $0.03 | $0.03 | $0.13 | · | |
| Cash Flow / Share | $-0.29 | $-0.32 | $-0.63 | · | |
| Cash / Share | $1.12 | $0.68 | $0.77 | · | |
| EPS (TTM) | $-0.34 | $-0.36 | $-0.96 | $-3.78 |
Wachstumsraten
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue YoY | 17.3% | -46.1% | 517.6% | · | |
| Revenue CAGR 3Y | 57.5% | · | · | · |
Bewertung (TTM)
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue TTM | $10M | $8M | $15M | $3M | |
| Net Income TTM | $-109M | $-89M | $-112M | $-166M | |
| Market Cap | $1.57B | $355M | $331M | · | |
| Enterprise Value | $1.30B | $259M | $227M | · | |
| P/E | -16.2 | -4.8 | -1.8 | -0.6 | |
| P/S | 160.4 | 42.5 | 21.4 | · | |
| P/B | 6.3 | 5.0 | 4.4 | · | |
| P / Tangible Book | 6.3 | 5.0 | 4.4 | 150.5 | |
| P / Cash Flow | -16.8 | -4.4 | -4.5 | · | |
| P / FCF | -16.7 | -4.3 | -4.3 | · | |
| EV / EBITDA | -11.7 | -2.8 | -3.1 | · | |
| EV / FCF | -13.8 | -3.2 | -3.0 | · | |
| EV / Revenue | 132.8 | 31.1 | 14.7 | · | |
| Earnings Yield | -6.2% | -20.8% | -54.2% | -167.3% |
Gewinn- und Verlustrechnung
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $5M | $0 | $2M | $2M | $2M | $2M | $1M | $3M | $4M | $5M | $2M | $5M | |
| R&D Expense | $39M | $34M | $25M | $26M | $20M | $16M | $15M | $15M | $15M | $21M | $13M | $12M | $20M | $13M | |
| SG&A Expense | $12M | $10M | $9M | $8M | $9M | $8M | $7M | $8M | $7M | $7M | $7M | $9M | $6M | $9M | |
| Operating Expenses | $47M | $43M | $34M | $34M | $29M | $24M | $22M | $28M | $22M | $28M | $20M | $21M | $26M | $21M | |
| Operating Income | $-47M | $-43M | $-28M | $-34M | $-27M | $-21M | $-20M | $-26M | $-21M | $-24M | $-16M | $-16M | $-23M | $-17M | |
| Interest Expense | · | · | · | · | · | · | · | · | $27.0K | $29.0K | · | $1M | $1M | $1M | |
| Interest Income | $2M | $3M | $3M | $3M | $2M | $1M | $2M | $2M | $1M | $2M | $2M | $1M | · | · | |
| Other Non-op | $-88.0K | $-31.0K | $-30.0K | $-37.0K | $-237.0K | $13.0K | $-66.0K | $-81.0K | $42.0K | $-5.0K | $-23.0K | $-19.0K | $3.0K | $-8.0K | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | · | $0 | $0 | $0 | |
| Net Income | $-47M | $-42M | $-28M | $-33M | $-27M | $-22M | $-19M | $-26M | $-21M | $-24M | $48M | $-117M | $-25M | $-18M | |
| EPS (Basic) | $-0.13 | $-0.12 | $-0.08 | $-0.09 | $-0.09 | $-0.08 | $-0.07 | $-0.10 | $-0.09 | $-0.10 | $0.63 | $-0.93 | $-0.38 | $-0.28 | |
| EPS (Diluted) | $-0.13 | $-0.12 | $-0.08 | $-0.09 | $-0.09 | $-0.08 | $-0.07 | $-0.10 | $-0.09 | $-0.10 | $0.63 | $-0.93 | $-0.38 | $-0.28 | |
| Shares (Basic) | 369,044,040 | 366,632,827 | · | 353,309,524 | 297,988,978 | 269,306,331 | · | 267,824,045 | 232,821,553 | 231,249,344 | · | 125,700,799 | 64,244,531 | 63,260,905 | |
| Shares (Diluted) | 369,044,040 | 366,632,827 | · | 353,309,524 | 297,988,978 | 269,306,331 | · | 267,824,045 | 232,821,553 | 231,249,344 | · | 125,700,799 | 64,244,531 | 63,260,905 | |
| EBITDA | $-47M | $-43M | · | $-34M | $-27M | $-21M | · | $-26M | $-21M | $-24M | · | $-16M | $-23M | $-17M |
Bilanz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $455M | $277M | $320M | $297M | $313M | $117M | $139M | $158M | $173M | $124M | $144M | $164M | $45M | $63M | |
| Prepaid Expense | $6M | $5M | $4M | $2M | $3M | $4M | $3M | $3M | $3M | $4M | $3M | $6M | $9M | $9M | |
| Other Current Assets | $851.0K | $1M | $802.0K | $456.0K | $657.0K | $536.0K | $308.0K | $465.0K | $206.0K | $149.0K | $292.0K | $404.0K | $510.0K | $532.0K | |
| Current Assets | $461M | $282M | $325M | $300M | $316M | $121M | $142M | $162M | $178M | $131M | $150M | $172M | $54M | $72M | |
| PP&E (Net) | $2M | $6M | $7M | $7M | $7M | $7M | $7M | $8M | $11M | $11M | $11M | $11M | $14M | $15M | |
| PP&E (Gross) | $8M | $11M | $11M | $11M | $11M | $11M | $11M | $12M | $14M | $14M | $14M | $14M | $16M | $17M | |
| Accum. Depreciation | $5M | $5M | $5M | $4M | $4M | $4M | $4M | $4M | $4M | $3M | $3M | $3M | $2M | $2M | |
| Other Non-current Assets | $106.0K | $181.0K | $183.0K | $184.0K | $186.0K | $188.0K | $217.0K | $220.0K | $288.0K | $304.0K | $304.0K | $304.0K | $304.0K | $1M | |
| Total Assets | $470M | $300M | $343M | $317M | $333M | $138M | $160M | $180M | $200M | $153M | $173M | $196M | $82M | $102M | |
| Accounts Payable | $9M | $5M | $6M | $5M | $8M | $4M | $4M | $5M | $9M | $10M | $6M | $8M | $11M | $9M | |
| Current Liabilities | $26M | $20M | $27M | $29M | $25M | $23M | $26M | $29M | $34M | $39M | $37M | $180M | $51M | $54M | |
| Capital Leases | $6M | $18M | $18M | $17M | $17M | $17M | $17M | $18M | $18M | $18M | $19M | $19M | $20M | $20M | |
| Other Non-current Liabilities | $2M | $2M | $2M | $2M | $1M | $1M | $1M | $1M | $1M | $2M | $2M | $4M | $4M | $4M | |
| Total Liabilities | $83M | $88M | $96M | $98M | $85M | $83M | $89M | $91M | $92M | $99M | $98M | $245M | $119M | $117M | |
| Long-term Debt | · | · | · | · | · | · | · | · | · | · | · | · | $38M | $38M | |
| Total Debt | $49M | $49M | · | $51M | $41M | $42M | · | $43M | $38M | $41M | · | $39M | $38M | $38M | |
| Common Stock | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $1.0K | $1.0K | |
| Paid-in Capital | $1.19B | $965M | $958M | $904M | $900M | $681M | $678M | $675M | $664M | $591M | $588M | $512M | $407M | $404M | |
| Retained Earnings | $-800M | $-754M | $-711M | $-683M | $-651M | $-624M | $-602M | $-584M | $-558M | $-537M | $-513M | $-561M | $-444M | $-419M | |
| AOCI | $769.0K | $985.0K | $-192.0K | $-1M | $-699.0K | $-2M | $-4M | $-2M | $2M | $-251.0K | · | · | · | · | |
| Stockholders' Equity | $387M | $212M | $247M | $219M | $249M | $55M | $72M | $89M | $109M | $54M | $75M | $-49M | $-37M | $-15M | |
| Liabilities + Equity | $470M | $300M | $343M | $317M | $333M | $138M | $160M | $180M | $200M | $153M | $173M | $196M | $82M | $102M | |
| Shares Outstanding | 325,302,280 | 287,276,885 | 285,051,648 | 273,915,373 | 272,730,060 | 205,054,570 | 204,943,306 | 204,943,306 | 201,381,450 | 187,018,275 | 186,960,193 | 186,960,193 | 64,432,637 | 63,473,349 |
Cashflow
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $6M | $6M | $4M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $2M | $2M | $2M | $2M | |
| Operating Cash Flow | $-40M | $-41M | $-27M | $-24M | $-20M | $-22M | $-18M | $-22M | $-22M | $-20M | $-16M | $-18M | $-19M | $-20M | |
| CapEx | $-1.0K | $24.0K | $250.0K | $108.0K | $2.0K | $378.0K | $-2.0K | $35.0K | $201.0K | $140.0K | $17.0K | $0 | $-48.0K | $4M | |
| Investing Cash Flow | $1.0K | $-3M | $-247.0K | $-48.0K | $62.0K | $-371.0K | $13.0K | $-35.0K | $-201.0K | $-140.0K | $-10.0K | $-3M | $48.0K | $-4M | |
| Stock Issued | · | · | · | · | · | · | · | · | · | · | $0 | · | · | · | |
| Financing Cash Flow | $217M | $711.0K | $50M | $9M | $216M | $-52.0K | $-357.0K | $7M | $70M | $-22.0K | $-4M | $141M | $377.0K | $-370.0K | |
| Net Change in Cash | $176M | $-43M | $23M | $-15M | $196M | $-22M | $-19M | $-15M | $49M | $-20M | $-20M | $119M | $-18M | $-24M | |
| Free Cash Flow | · | $-41M | · | · | · | · | · | · | · | $-20M | · | · | · | $-24M |
Rentabilität
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | · | -1347.1% | -930.5% | · | -1448.4% | -1915.4% | -713.3% | · | -342.4% | -976.4% | -351.9% | |
| Net Margin | · | · | · | · | -1353.6% | -935.2% | · | -1427.5% | -1882.0% | -705.4% | · | -2467.1% | -1027.1% | -374.5% | |
| EBITDA Margin | · | · | · | · | -1347.1% | -930.5% | · | -1448.4% | -1915.4% | -713.3% | · | -342.4% | -976.4% | -351.9% | |
| ROA | -11.6% | -19.3% | · | -13.2% | -10.1% | -14.8% | · | -13.6% | -14.8% | -18.9% | · | -76.2% | -22.0% | -13.2% | |
| ROE | -14.7% | -31.8% | · | -21.3% | -15.0% | -39.5% | · | -128.6% | -58.3% | -123.7% | · | 616.4% | 1117.1% | -98.5% |
Liquidität & Solvenz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 17.8 | 14.0 | · | 10.5 | 12.5 | 5.4 | · | 5.5 | 5.2 | 3.4 | · | 1.0 | 1.1 | 1.3 | |
| Quick Ratio | 17.5 | 13.8 | · | 10.4 | 12.3 | 5.2 | · | 5.4 | 5.1 | 3.2 | · | 0.9 | 0.9 | 1.2 | |
| Debt / Equity | 0.1 | 0.2 | · | 0.2 | 0.2 | 0.8 | · | 0.5 | 0.3 | 0.8 | · | -0.8 | -1.0 | -2.6 | |
| LT Debt / Equity | 0.1 | 0.2 | · | 0.2 | 0.2 | 0.8 | · | 0.5 | 0.3 | 0.8 | · | -0.8 | -1.0 | -2.6 | |
| Interest Coverage | · | · | · | · | · | · | · | · | -788.9 | -839.0 | · | -11.0 | -16.2 | -12.1 |
Effizienz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 |
Pro Aktie
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $1.19 | $0.74 | · | $0.80 | $0.91 | $0.27 | · | $0.43 | $0.54 | $0.29 | · | $-0.26 | $-0.58 | $-0.24 | |
| Revenue / Share | $0.00 | $0.00 | · | $0.00 | $0.01 | $0.01 | · | $0.01 | $0.00 | $0.01 | · | $0.04 | $0.04 | $0.07 | |
| Cash Flow / Share | · | $-0.11 | · | · | · | $-0.08 | · | · | · | $-0.09 | · | · | · | $-0.32 | |
| Cash / Share | $1.40 | $0.96 | · | $1.09 | $1.15 | $0.57 | · | $0.77 | $0.86 | $0.66 | · | $0.88 | $0.70 | $1.00 | |
| EPS (TTM) | $-0.42 | $-0.38 | · | $-0.33 | $-0.34 | $-0.34 | · | $0.34 | $-0.49 | $-0.78 | · | $-2.55 | $-2.27 | $-2.74 |
Bewertung (TTM)
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $5M | $7M | · | $6M | $8M | $7M | · | $10M | $13M | $14M | · | · | · | · | |
| Net Income TTM | $-150M | $-130M | · | $-100M | $-93M | $-87M | · | $-23M | $-114M | $-118M | · | $-214M | $-124M | $-133M | |
| Market Cap | $2.22B | $1.28B | · | $896M | $630M | $285M | · | $412M | $451M | $537M | · | $591M | $43M | $51M | |
| Enterprise Value | $1.81B | $1.06B | · | $649M | $358M | $211M | · | $297M | $316M | $453M | · | $465M | $36M | $25M | |
| P/E | -16.2 | -11.8 | · | -9.9 | -6.8 | -4.1 | · | 5.9 | -4.6 | -3.7 | · | -1.2 | -0.3 | -0.3 | |
| P/S | 403.9 | 171.9 | · | 141.9 | 77.8 | 39.5 | · | 41.5 | 35.0 | 37.9 | · | · | · | · | |
| P/B | 5.7 | 6.1 | · | 4.1 | 2.5 | 5.2 | · | 4.6 | 4.1 | 10.0 | · | -12.0 | -1.1 | -3.4 | |
| P / Tangible Book | 5.7 | 6.1 | · | 4.1 | 2.5 | 5.2 | · | 4.6 | 4.1 | 10.0 | · | · | · | · | |
| P / Cash Flow | · | -31.4 | · | · | · | -12.9 | · | · | · | -27.1 | · | · | · | -2.5 | |
| EV / Revenue | 329.8 | 141.4 | · | 102.9 | 44.2 | 29.2 | · | 30.0 | 24.6 | 32.0 | · | · | · | · | |
| Earnings Yield | -6.2% | -8.5% | · | -10.1% | -14.7% | -24.5% | · | 16.9% | -21.9% | -27.2% | · | -80.7% | -343.4% | -343.4% |
Aktuellster Zeitraum links · fehlende Werte werden als · angezeigt
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Umsatz | $10M | $8M | $15M | $3M | · |
| Betriebsgewinnmarge % | -1130.7% | -1097.5% | -468.8% | · | · |
| Nettoergebnis | $-109M | $-89M | $-112M | $-166M | $-175M |
| Verwässerte EPS | $-0.34 | $-0.36 | $-0.96 | $-3.78 | $-4.64 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Fremdkapital / Eigenkapital | 0.2 | 0.6 | 0.5 | · | 0.4 |
| Liquiditätsgrad | 12.2 | 5.4 | 4.1 | · | 3.1 |
| Quick Ratio | 12.0 | 5.3 | 3.9 | · | 2.9 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Freier Cashflow | $-94M | $-82M | $-77M | · | $-132M |
Institutionelle Eigentümer (13F) 221 Einreicher · $2.1B gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Inhaber
221
Gehaltener Wert
$2.1B
Neue Positionen
40
Geschlossene Positionen
23
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 40 (+5 vs. Vorquartal) | 23 (-7 vs. Vorquartal) | 101 (+29 vs. Vorquartal) | 41 (-10 vs. Vorquartal) | +34.4M |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| Avoro Capital Advisors LLC | $162.683.327 | 23.888.888 | 7,59% | Aktien |
| RA CAPITAL MANAGEMENT, L.P. | $160.413.963 | 23.555.648 | 7,48% | Aktien |
| GOLDMAN SACHS GROUP INC | $154.676.334 | 22.713.118 | 7,21% | Aktien |
| BlackRock, Inc. | $140.912.023 | 20.691.927 | 6,57% | Aktien |
| Vestal Point Capital, LP | $132.216.150 | 19.415.000 | 6,17% | Aktien |
| MORGAN STANLEY | $112.279.731 | 16.487.479 | 5,24% | Aktien |
| RTW INVESTMENTS, LP | $92.345.357 | 13.560.258 | 4,31% | Aktien |
| FMR LLC | $90.820.969 | 13.336.413 | 4,24% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $84.979.232 | 12.478.595 | 3,96% | Aktien |
| STATE STREET CORP | $77.783.275 | 11.421.920 | 3,63% | Aktien |
| VANGUARD GROUP INC | $72.972.929 | 13.267.805 | 3,40% | Aktien |
| Siren, L.L.C. | $67.055.203 | 9.846.579 | 3,13% | Aktien |
| Octagon Capital Advisors LP | $66.010.992 | 9.693.244 | 3,08% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $44.685.322 | 6.560.394 | 2,08% | Aktien |
| Polar Capital Holdings Plc | $34.847.676 | 5.117.133 | 1,63% | Aktien |
| MPM BIOIMPACT LLC | $30.645.000 | 4.500.000 | 1,43% | Aktien |
| D. E. Shaw & Co., Inc. | $29.954.821 | 4.398.652 | 1,40% | Aktien |
| BAKER BROS. ADVISORS LP | $27.272.388 | 4.004.756 | 1,27% | Aktien |
| WELLINGTON MANAGEMENT GROUP LLP | $27.073.870 | 3.975.605 | 1,26% | Aktien |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | $26.460.262 | 3.885.501 | 1,23% | Aktien |
| GordonMD Global Investments LP | $24.501.508 | 723.185 | 1,14% | Aktien |
| Casdin Capital, LLC | $22.132.500 | 3.250.000 | 1,03% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $21.383.461 | 3.140.009 | 1,00% | Aktien |
| ADAR1 Capital Management, LLC | $20.705.573 | 3.040.466 | 0,97% | Aktien |
| Pictet Asset Management Holding SA | $18.868.474 | 2.770.701 | 0,88% | Aktien |
| Aberdeen Group plc | $15.847.905 | 2.327.152 | 0,74% | Aktien |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | $15.322.500 | 2.250.000 | 0,71% | Aktien |
| NORGES BANK | $15.210.816 | 2.233.600 | 0,71% | Aktien |
| NORTHERN TRUST CORP | $15.160.491 | 2.226.210 | 0,71% | Aktien |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $14.986.733 | 2.200.695 | 0,70% | Aktien |
| MILLENNIUM MANAGEMENT LLC | $14.483.767 | 2.126.838 | 0,68% | Aktien |
| ORBIMED ADVISORS LLC | $13.620.000 | 2.000.000 | 0,64% | Aktien |
| RICE HALL JAMES & ASSOCIATES, LLC | $13.567.079 | 1.992.229 | 0,63% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $12.914.988 | 1.896.474 | 0,60% | Aktien |
| B Group, Inc. | $12.261.786 | 1.800.556 | 0,57% | Aktien |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | $12.099.000 | 3.700.000 | 0,56% | Aktien |
| Affinity Asset Advisors, LLC | $11.917.500 | 1.750.000 | 0,56% | Aktien |
| BARCLAYS PLC | $11.104.787 | 1.630.659 | 0,52% | Aktien |
| CITADEL ADVISORS LLC | $10.455.305 | 1.535.287 | 0,49% | Aktien |
| HEIGHTS CAPITAL MANAGEMENT, INC | $10.215.000 | 1.500.000 | 0,48% | Aktien |
| Seven Fleet Capital Management LP | $9.940.323 | 1.504.400 | 0,46% | Aktien |
| Palo Alto Investors LP | $9.475.311 | 1.391.382 | 0,44% | Aktien |
| BANK OF AMERICA CORP /DE/ | $9.349.074 | 1.372.845 | 0,44% | Aktien |
| Granahan Investment Management, LLC | $8.888.255 | 1.305.177 | 0,41% | Aktien |
| Quantum Private Wealth, LLC | $5.529.903 | 812.027 | 0,26% | Aktien |
| FIRST TRUST ADVISORS LP | $5.387.860 | 791.169 | 0,25% | Aktien |
| JPMORGAN CHASE & CO | $5.157.078 | 766.282 | 0,24% | Aktien |
| Sands Capital Alternatives, LLC | $4.936.385 | 724.873 | 0,23% | Aktien |
| Bank of New York Mellon Corp | $4.753.180 | 697.971 | 0,22% | Aktien |
| BNP PARIBAS FINANCIAL MARKETS | $4.358.638 | 640.035 | 0,20% | Aktien |
Aktivisten & 5%+-Eigentümer 4 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| Paul B Manning, The Paul B. Manning Revocable Trust dated May 10, 2000, The PBM 2023 Grantor Retained Annuity Trust, The PBM 2025 Grantor Retained Annuity Trust, BKB Growth Investments, LLC, BKB G2 Investments, LLC | 3. Juni 2025 | 9,80% | Änderung | · | SEC |
| Paul B. Manning, The Paul B. Manning Revocable Trust dated May 10, 2000, The PBM 2023 Grantor Retained Annuity Trust, BKB Growth Investments, LLC, BKB G2 Investments, LLC ×3 Einreichungen | 21. August 2023 | · | Erste Einreichung | · | SEC |
| Astellas Pharma Inc., Astellas US Holding, Inc., Astellas Gene Therapies, Inc. (f/k/a Audentes Therapeutics, Inc.) ×2 Einreichungen | 18. August 2023 | · | Erste Einreichung | · | SEC |
| RA Session II, RA Session II, as Trustee of the Session 2020 Annuity Trust I, RA Session II, as Trustee of the Session 2020 Annuity Trust II | 5. Oktober 2020 | · | Erste Einreichung | Passive Anlage | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Unternehmensinsider 11 Insider · 4 Führungskräfte · 7 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Sean P. Nolan | Chief Executive Officer | 26. Januar 2026 S | 2.908.257 | 0 | 2 | $-840.196 |
| Kamran Alam | CHIEF FINANCIAL OFFICER | 4. Februar 2026 S | 1.442.131 | 0 | 3 | $-492.523 |
| Sukumar Nagendran | President and Head of R&D | 10. April 2026 M | 1.136.410 | 0 | 6 | $-4.077.375 |
| Suyash Prasad | CMO and Head of R&D | 6. Juli 2022 S | 530.589 | 0 | 0 | $0 |
| Alison S Long | Direktor | 2. Juni 2025 A | 105.843 | 0 | 0 | $0 |
| Laura Sepp-Lorenzino | Direktor | 2. Juni 2025 A | 105.843 | 0 | 0 | $0 |
| John A Stalfort III | Direktor | 2. Juni 2025 A | 1.155.224 | 0 | 0 | $0 |
| Phillip B. Donenberg | Direktor | 2. Juni 2025 A | 219.954 | 0 | 0 | $0 |
| Kathleen Reape | Direktor | 22. Juni 2023 A | · | 0 | 0 | $0 |
| Paul B Manning | 10%-Eigentümer | 30. Mai 2025 P | 2.841.704 | 0 | 0 | $0 |
| R.A. Session II | 10%-Eigentümer | 13. Juli 2023 S | 8.871.747 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
ETF-Besitz Gehalten von 34 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| IBRN · iShares Trust | 1,29% | 18.665 SH | 11. September 2026 | Täglich |
| BBC · ETFis Series Trust I | 0,69% | 54.433 NS | 31. Juli 2026 | N-PORT |
| FYC · First Trust Exchange-Traded AlphaDE… | 0,34% | 758.584 NS | 31. Juli 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,22% | 189.117 NS | 31. Juli 2026 | N-PORT |
| ESSC · Strategy Shares | 0,15% | 9.374 NS | 31. Juli 2026 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0,11% | 332.492 SH | 19. August 2026 | Täglich |
| FYX · First Trust Exchange-Traded AlphaDE… | 0,11% | 256.192 NS | 31. Juli 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,10% | 23.041 SH | 1. Oktober 2026 | Täglich |
| IBB · iShares Trust | 0,10% | 2.030.172 SH | 11. September 2026 | Täglich |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,10% | 257.044 SH | 19. August 2026 | Täglich |
| IWO · iShares Trust | 0,08% | 2.238.896 SH | 11. September 2026 | Täglich |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,07% | 68.720 NS | 31. Juli 2026 | N-PORT |
| PWS · Pacer Funds Trust | 0,06% | 2.584 NS | 31. Juli 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,05% | 1.379.816 SH | 19. August 2026 | Täglich |
| RSSL · Global X Funds | 0,05% | 114.788 NS | 31. Juli 2026 | N-PORT |
| IWM · iShares Trust | 0,04% | 6.131.004 SH | 11. September 2026 | Täglich |
| ISCG · iShares Trust | 0,04% | 66.643 SH | 11. September 2026 | Täglich |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,02% | 117.429 SH | 1. Oktober 2026 | Täglich |
| VXF · VANGUARD INDEX FUNDS | 0,02% | 3.043.718 SH | 19. August 2026 | Täglich |
| VHT · VANGUARD WORLD FUND | 0,02% | 552.457 SH | 19. August 2026 | Täglich |
| TEXN · iShares Trust | 0,02% | 680 SH | 11. September 2026 | Täglich |
| FHLC · FIDELITY COVINGTON TRUST | 0,02% | 87.466 NS | 31. Juli 2026 | N-PORT |
| WSML · iShares Trust | 0,01% | 8.303 SH | 11. September 2026 | Täglich |
| DFAS · Dimensional ETF Trust | 0,00% | 78.390 NS | 31. Juli 2026 | N-PORT |
| TILT · FlexShares Trust | 0,00% | 9.954 NS | 31. Juli 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 332.286 SH | 11. September 2026 | Täglich |
| IWV · iShares Trust | 0,00% | 70.755 SH | 11. September 2026 | Täglich |
| DCOR · Dimensional ETF Trust | 0,00% | 4.760 NS | 31. Juli 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0,00% | 5.870 NS | 31. Juli 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,00% | 3.045 NS | 31. Juli 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,00% | 10.179 NS | 31. Juli 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 9.141.487 SH | 19. August 2026 | Täglich |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 20.636 SH | 19. August 2026 | Täglich |
| ISCB · iShares Trust | · | 9.303 SH | 11. September 2026 | Täglich |
TSHA Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
Bewertung · 18 Analysten
KAUF
Median-Ziel
$12.00
+159,2%
6 33,3%
Starker Kauf
11 61,1%
Kauf
1 5,6%
Halten
0 0,0%
Verkauf
0 0,0%
Starker Verkauf
12-Monats-Kursziel
13 Analysten · 2026-09-27Mittelwert-Ziel $13.00 +180,8%
← Unter allen Zielen
Aktueller Preis $4.63
Tief$9.00
Mittelwert$13.00
Hoch$19.00
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
FY-Basis, Kurse zum Schlusskurs am Ende des letzten Geschäftsjahres jedes Unternehmens.
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| TSHA | $1.57B | -16.2 | 17.3% | -1115.3% | -44.0% | · |
| STOK | $1.87B | -264.5 | 404.5% | -3.7% | -2.0% | · |
| ZYME | $1.97B | -24.4 | 38.9% | -76.6% | -26.9% | · |
| XNCR | $1.10B | -12.3 | 13.7% | -73.2% | -14.0% | · |
| SNDX | $1.84B | -6.4 | 627.8% | -165.6% | -257.1% | · |
| RARE | $2.22B | -3.9 | 20.2% | -85.4% | -1613.2% | · |
| COAG | · | · | · | · | · | · |
| ANAB | · | -105.4 | 157.0% | · | · | · |
| INBX | $1.15B | -8.7 | 550.0% | -10773.5% | -365.9% | · |
| TYRA | $1.41B | -13.1 | · | · | -42.7% | · |
Neueste Nachrichten Aktuelle Schlagzeilen über dieses Unternehmen
Taysha Gene Therapies (TSHA) berichtet über die finanziellen Ergebnisse für Q1 2026
Yahoo Finance · 4 Monate, 2 Wochen vor
Canaccord behält Kauf-Rating für Taysha (TSHA) nach Q1-Highlights
Yahoo Finance · 4 Monate, 2 Wochen vor
Taysha Gene Therapies (TSHA) Aktienkurs steigt um 343,45 % gegenüber dem Vorjahresniveau
Yahoo Finance · 5 Monate, 1 Woche vor
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das + neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Quelle: SEC 10-Q eingereicht Aug 11, 2026